Live tape
Top 8, mentions 7d14,333GOOGL2,869 mentions▲ +0.04NVDA2,215 mentions▲ +0.05AMD1,940 mentions▲ +0.08QQQ1,751 mentions▲ +0.05AAPL1,729 mentions▲ +0.05SPY1,560 mentions▲ +0.06TSLA1,164 mentions▲ +0.06SPCX1,105 mentions▲ +0.05

Equity · Healthcare

RCUS

NYSE

Arcus Biosciences (RCUS)

27.38 USD +1.41% vs prior close
Arcus Biosciences, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for RCUS to draw a line in its place.

Track this symbol on TradingView
Market cap
3.9B USD
Revenue, year to Dec 2025
33.0M USD
EPS, diluted, year to Dec 2025
−3.29 USD
52-week range
9 USD – 31.01 USD
Avg volume
273.6K

as of Jul 17, 2026

Have Arcus Biosciences (RCUS) insiders bought or sold shares recently?

RCUS has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 21 August 2026.

Form 4

Have Arcus Biosciences (RCUS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Aug 2026Azoy AlexanderChief Accounting OfficerSell2,82785K USD
10 Jul 2026Jaen Juan C.PresidentSell20,067574K USD
09 Jul 2026Jaen Juan C.PresidentSell48,5021.5M USD
24 Jun 2026Jaen Juan C.PresidentSell6,431191K USD
23 Jun 2026Jaen Juan C.PresidentSell15,764437K USD
22 Jun 2026Jaen Juan C.PresidentSell9,236250K USD
01 Jun 2026Azoy AlexanderChief Accounting OfficerSell2,56266K USD
11 May 2026Goeltz II Robert C.Chief Financial OfficerSell7,763199K USD
05 Jan 2026Jaen Juan C.PresidentSell31,823681K USD
31 Dec 2025Goeltz II Robert C.Chief Financial OfficerSell6,552153K USD
18 Dec 2025Azoy AlexanderChief Accounting OfficerSell4,34397K USD
17 Dec 2025ROSEN TERRY JChief Executive OfficerSell25,744570K USD
Sold37 open-market sales640,795$14.37M

Showing the 12 most recent of 37 open-market trades in this window. The figures above count all of them.

23 other filings: grants, exercises, tax withholding and transfers, not trades
Have Arcus Biosciences (RCUS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Aug 2026Azoy AlexanderChief Accounting OfficerOption exercise2,82744K USD
11 Jun 2026PERLMAN ANDREW JDirectorAward5,700
11 Jun 2026FALBERG KATHRYN EDirectorAward5,700
11 Jun 2026KANEKO YASUNORIDirectorAward5,700
11 Jun 2026Machado PatrickDirectorAward5,700
11 Jun 2026Lacey David L.DirectorAward5,700
11 Jun 2026Lambert NicoleDirectorAward5,700
11 Jun 2026Ribas AntoniDirectorAward5,700
11 Jun 2026Tang Carolyn C.General CounselOption exercise34,09088K USD
23 Jan 2026ROSEN TERRY JChief Executive OfficerAward79,000
23 Jan 2026Jaen Juan C.PresidentAward31,000
23 Jan 2026Goeltz II Robert C.Chief Financial OfficerAward24,000

Showing the 12 most recent of 23 compensation filings in this window. The figures above count all of them.

Which funds hold Arcus Biosciences (RCUS)?

1 of the 45 institutional funds we track reported a Arcus Biosciences position for the quarter ended 30 Sep 2026 — a combined 49.6M USD; the latest of those filings landed 06 Nov 2026.

Form 13F

Which funds hold Arcus Biosciences (RCUS)?
FundPositionSharesValueShares q/q
Fisher Asset ManagementHeld (±25%)1,918,49749.6M USD−10.3%

What has been filed or recorded for Arcus Biosciences (RCUS)?

The filings we hold for Arcus Biosciences, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Arcus Biosciences (RCUS)?
And
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −1.00 USDRevenue $9M
30 Sep 2026FinancialsTotal assets818.0M USDat period end
30 Sep 2026FinancialsTotal equity358.0M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.72 USDRevenue $41M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.02 USDRevenue $17M
31 Dec 2025Annual reportFY 2025 reportedEPS −3.29 USDRevenue $247M
31 Dec 2025FinancialsRevenue33.0M USDfiscal year
31 Dec 2025FinancialsNet income−353.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.29 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.27 USDRevenue $26M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.00 USDRevenue $160M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1.14 USDRevenue $28M
31 Dec 2024Annual reportFY 2024 reportedEPS −3.14 USDRevenue $258M

Arcus Biosciences (RCUS): frequently asked questions

From live data
3.9B

What is Arcus Biosciences’ market cap?

Arcus Biosciences is worth 3.9B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

33.0M

What is Arcus Biosciences’ revenue?

Arcus Biosciences reported revenue of 33.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Arcus Biosciences insiders bought or sold shares recently?

No Arcus Biosciences insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 21 Aug 2026 (SEC Form 4). See Insiders

1 of 45

Which funds own Arcus Biosciences?

1 of the 45 funds we track reported a Arcus Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds

−1.00

When did Arcus Biosciences last report earnings?

Arcus Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.00 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings